Health Care/Hospital

OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

--CUSP06 is a CDH6-directed Antibody-Drug Conjugate (ADC) with a differentiated profile and potentially best-in-class activity-- NEW YORK, March 6, 2024 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innova...

2024-03-06 21:00 1252

APAX Medical Introduces Cutting-Edge ADVATx Laser For Skin Rejuvenation

SINGAPORE, March 6, 2024 /PRNewswire/ -- APAX Medical & Aesthetics Clinic is proud to announce the introduction of the ADVATx laser treatment by Advalight in their offerings - a revolutionary laser system that targets both active acne and acne scars simultaneously. This innovative solution utilis...

2024-03-06 20:22 1982

Latest Updates of Viva Biotech's Portfolio Companies

HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies up to date and promotes the evolution of R&D and the suc...

2024-03-06 19:33 2270

American, Finnish and Canadian governments fund oxygen plant at Tatu City SEZ, Kenya

Project will combat infant mortality rates and lessen fetal distress in East Africa TATU CITY, Kenya, March 6, 2024 /PRNewswire/ -- The governments of the United States, Finland and Canada are funding a sustainable, accessible and affordable medicinal oxygen manufacturing facility at Tatu City S...

2024-03-06 18:48 2176

Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC

HONG KONG, March 6, 2024 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced the enrollment of the first patient in the registrational Phase III clinical study comparingCadonilimab (PD-1/CTLA-4 bispecific antibody) combined with chemotherapy versus Tislelizumab (PD-1 antibody) combined with ...

2024-03-06 18:07 1955

MAG GROUP HOLDING RECORDS OVER AED 12.6 BILLION SALES IN 2023

DUBAI, UAE, March 6, 2024 /PRNewswire/ -- MAG Group Holding, the multinational conglomerate incorporating different companies across diverse sectors, announced the recording of AED 12.6 billion in sales for 2023 across its different real estate subsidiaries.

2024-03-06 18:00 2844

NIPPON EXPRESS HOLDINGS Acquires Stake in Instalimb, Japan's Startup Expanding 3D-printed Prosthetics Business Overseas

- Helping to Achieve Sustainable Societies Allowing All People to Lead Affluent and Fulfilling Lives - TOKYO, March 6, 2024 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC. acquired an equity stake in Instalimb, Inc. (hereinafter "Instalimb"), which is expanding its 3D-printed prosthetics business ...

2024-03-06 14:00 2449

Innovative Visionary Mark W. Womack Strengthens Bridgewest Perth Pharma Pty Ltd Board, Amplifying NovaCina's Growth Vision

Mark W. Womack Named to Bridgewest Perth Pharma Pty Ltd Board of Directors MIAMI and PERTH, Australia, March 6, 2024 /PRNewswire/ -- Bridgewest Perth Pharma, a global pharmaceutical supply and manufacturing company, with subsidiaries NovaCina and LumaCina, announced today the appointment ofMark W...

2024-03-06 12:29 2053

AACR 2024 | Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting

ROCKVILLE, Md. and SUZHOU, China, March 5, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, age-related diseases, and chronic hepatitis B (CHB), announced today that the latest results from three preclinical stud...

2024-03-06 08:59 3107

Everest Medicines to Announce Full-Year 2023 Financial Results on March 28, 2024

SHANGHAI, March 6, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the fu...

2024-03-06 08:59 2242

Laminar Pharmaceuticals S.A. receives recommendation from the Independent Data Monitoring Committee to advance to the next stage of CLINGLIO, the phase 2b/3 Clinical Trial of LAM561 in combination with RT and TMZ for adults with newly diagnosed glioblastoma

The independent data monitoring committee (IDMC) has recommended continuation of CLINGLIO without modification after its assessment of LAM561 interim efficacy in newly diagnosed Glioblastoma. This follows the previous recommendation in relation to safety. CLINGLIO remains on track to have its op...

2024-03-06 08:45 2041

Antengene to Present Four Preclinical Abstracts at AACR 2024, Highlighting Focus on Cancer Immunology, Targeted Agents and Novel Technology Platforms

* The first preclinical abstract on ATG-O42 (MTAPnull-selective small molecule PRMT5 inhibitor) as well as the latest data on the proprietary T cell engager platform, AnTenGagerTM, and ATG-102 (LILRB4 x CD3 T cell engager). * The first view of ATG-022 (Claudin 18.2 ADC) companion diagnostic. S...

2024-03-06 08:30 2328

Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024

* Presentations will highlight the broad potential treatment opportunities for its clinical-stage targeted therapeutics HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) with further demonstrations of their pre-clinical efficacy in additional indications and deeper studies of their underly...

2024-03-06 05:30 2021

Life Fitness Delivers on the Future of Fitness, Debuting State-of-the-Art Cardio Line with Next-Gen Biomechanics, Symbio™, at IHRSA 2024

ROSEMONT, Ill., March 6, 2024 /PRNewswire/ -- Life Fitness, the global leader in commercial fitness equipment, will unveil a new generation of cardio, strength training, and digital product innovations at the 2024 IHRSA Convention & Trade Show. Life Fitness' latest innovations builds on the compa...

2024-03-06 00:00 3432

Datasea Expects Approximately 1,128% Revenue Growth in 2024

BEIJING, March 5, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative business segments for Acoustics Intelligence and 5G-AI multimodal communication technology inChina and the US, issued guidance today for expecting a revenue o...

2024-03-05 23:45 3016

Zymo Research Pioneers a Breakthrough in Large-scale Animal-free RNase A Production

IRVINE, Calif., March 5, 2024 /PRNewswire/ -- In a groundbreaking development, Zymo Research, a leader in biotechnology innovation, has revolutionized large-scale production of animal-free recombinant RNase A ( PureRec RNase A), a challenge that persisted for over half a century. This breakthroug...

2024-03-05 22:00 1587

Laifen Launches the Laifen Wave Electric Toothbrush, a Revolutionary New Oral Health and Wellness Experience

Laifen's Newest Self-Care Innovation is Now Available to Purchase in the U.S. HONG KONG, March 5, 2024 /PRNewswire/ -- Laifen , a renowned leader in personal care appliances, is pleas...

2024-03-05 22:00 1681

DaVita enters into agreement to expand operations in Brazil and Colombia, enter Chile and Ecuador

Expansion would make DaVita the largest dialysis services provider in Latin America DENVER, March 5, 2024 /PRNewswire/ -- DaVita Inc (NYSE: DVA), a leading provider of kidney care services, today announced that it has agreed to terms on the expansion of its international operations inBrazil and ...

2024-03-05 22:00 3825

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

GAITHERSBURG, Md., March 5, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious disea...

2024-03-05 21:00 2815

Angel Yeast Hosts Webinar with PPTI to Promote Sustainable Development of Proteins

SHANGHAI, March 5, 2024 /PRNewswire/ -- Angel Yeast , (SH600298), the world's leading yeast manufacturer, recently successfully hosted a webinar event with Protein Production Technology International (PPTI), a digital publication dedicated to the alternative proteins sp...

2024-03-05 21:00 2850
1 ... 120121122123124125126 ... 848

Week's Top Stories